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Hospital-at-Home (HaH) is a unique care model that allows for the provision of inpatient level 
care in the patient’s home. HaH has been used to facilitate early discharge from inpatient care or 
to substitute entirely for an inpatient admission. Hospital-at-Home has been shown to have similar 
clinical outcomes to inpatient care, while reducing cost and complications associated with inpatient 
admission. Application of the HaH model to patients with oncologic disease is a promising avenue 
to reduce healthcare costs while improving patients’ quality of life by increasing time spent at 
home. A major challenge to implementing a Hospital-at-Home program for cancer patients is the 
lack of validated criteria to inform the selection of admissions most suitable for home-based 
hospital level care. 
Methods and Results: 
Admissions to the Yale New Haven Smilow Cancer Hospital’s medical oncology floor in New 
Haven from Jan 2015- Jun 2019 were included in the analysis (N=3,322). The analysis focused 
entirely on patients with solid tumors hospitalized for unplanned admissions. The definition of 
suitability for HaH was based on a substitutive model and identified admissions that did not receive 
any services that would be difficult to deliver or were inconsistent with safe care in the home. 
Twenty-seven-point-three percent of admissions were identified as suitable for HaH, accounting 
for 908 admissions during the study period. Admissions that were suitable for HaH were shorter 
in duration (2.79 vs 6.41 days), more likely to result in discharge home rather than to other 
healthcare facility (87.5% vs 69.5%), and less likely to be readmitted in the following 30 days 
(25.3% vs 31.5%). A predictive logistic model constructed using a purposeful selection process 
identified 13 statistically significant predictors for suitability for HaH: Black/African American 
race (vs all other), observation status, patient evaluated in the emergency department (ED) or 
oncology extended care center (vs admitted directly from clinic), primary admission diagnosis of 
secondary malignancy, primary admission diagnosis of fever, primary admission diagnosis of 
digestive diseases, oncology diagnosis of secondary or unknown malignancy, initial pre-admission 
respiratory rate >20 breaths/min, final pre-admission systolic blood pressure <100 mmHg, final 
pre-admission temperature >100o F, Sodium < 135 mmol/L, hemoglobin <10 g/dL and ED visit in 
the previous 90 days. The predictive model had moderate discrimination (c-statistic 0.686) and 
was well calibrated in the validation cohort (Hosmer-Lemeshow P-value >0.05). 
Conclusion: 
We describe the first predictive model of suitability for Hospital-at-Home in oncology patients. 
This model serves as a starting point to creating selection criteria and can be further refined and 
tested in prospective validation and pilot studies. The modest discrimination of the model indicates 
that much of the variability that allows for accurate prediction is still unaccounted for and would 
benefit from larger studies and inclusion of clinician judgement.   
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With the rising prevalence of cancer the United States, treatment for cancer and its complications 
is becoming a larger part of healthcare and a significant contributor to costs [1,2]. A significant 
portion of that cost comes from inpatient care, with the cost of inpatient treatment for patients with 
cancer being 350% more expensive than similar patients without a cancer diagnosis [3]. Compared 
to those without a cancer diagnosis, patients with cancer are more likely to be admitted to the 
hospital after visiting the emergency department and have longer length of hospital stays [4–8]. 
Hospital-at-Home (HaH) is a care model designed to replace inpatient hospitalization for acute 
illnesses by providing the resources to care for patients in their homes [9]. HaH has been proposed 
as a way to reduce inpatient hospitalization for oncology patients [10]. One barrier to use of HaH 
in oncology patients is the lack of selection criteria to identify which admissions would potentially 
be safe for home-based hospital level care [10]. This study aims to inform the creation of such 
criteria by developing and validating a predictive model based on previous admissions to the 
medical oncology floor of Yale New Haven Hospital’s Smilow Cancer Hospital. 
History of Hospital-at-Home 
Modern medical HaH programs have been around since the late 1980s and are starting to gain 
momentum in United States. In Australia, they have become an important part of the healthcare 
delivery apparatus [11]. A review of studies of HaH among medical patients shows that outcomes 
are comparable to inpatient admission [12]. Reductions in the total cost of care and decreased 
utilization of healthcare resources such as laboratory studies have been observed in multiple 
settings [13–15]. The potential to increase satisfaction and quality while reducing costs makes 
HaH a promising addition to the broader healthcare delivery system [16]. In the context of the 
larger healthcare system, HaH provides an avenue for better allocation of costly hospital resources 
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toward high risk patients, while allowing relatively stable patients to receive care in the home for 
their acute illness. 
House calls and home care were common in healthcare until the 20th century when the rise of the 
hospital was fueled by the rapid advances in pharmacology and medical technology, the rise of 
multiple payors, and increased concerns about liability and accountability [17]. Early HaH models 
were developed and tested in Israel, England, and the United States [17–26]. Early successes led 
to expansion of models and continued scholarship, especially within public health systems and 
markets that had strong alignment between payors and providers. While there has been increasing 
interest in HaH in the United States, broad expansion has been limited by lack of a favorable 
funding mechanism [27].    
Early studies in the 1990s established the feasibility of hospital at home and motivated interest 
around the world. The Edward Hines Jr VA in Chicago had developed a hospital-based home care 
program in 1971 and in 1992 they published a randomized trial comparing hospital and home care 
admission for terminally ill veterans. While in many aspects this was a study focusing on home-
based hospice care, it was one of the first studies to show that home care could be used to replace 
hospital care for a broad range of diagnoses. This study reported an average reduction in 5.9 
hospital days per patient leading to an 18% reduction in cost with no difference in clinical 
outcomes (survival, activities of daily living, and cognitive function) and significant improvement 
in patient and caregiver satisfaction [18]. From 1995-98, a series of randomized trials of HaH were 
published in the British Medical Journal. Taken together they showed that for many conditions, 
there was no significant difference in clinical outcomes between patients randomized to HaH 
verses inpatient care, with some improvements in patient satisfaction and significant patient 
preference for HaH. The studies showed mixed results when it came to cost analysis and length of 
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stay [22,23,28].   The clinical outcomes measured included mortality, readmission, Dartmouth 
Cooperative Functional Assessment Charts, SF-36 to measure mobility, COPD disease 
questionnaire, and Barthel Index for activities of daily living. The HaH programs implemented in 
these studies varied in their use of physician supervision, and whether the programs diverted 
patients from an inpatient admission or served as a pathway for early discharge. A common critique 
of the early hospital-at-home studies is that the heterogeneity of models makes it difficult to 
compare programs and differentiate them from home-based skilled nursing care or chronic 
ambulatory care [29,30]. There have been proposals to tighten the definition of HaH to those 
programs that substitute entirely for inpatient admission and provide around-the clock services 
similar to what is available in an inpatient setting [30]. Highlighting this distinction, separate 
Cochrane reviews are devoted to analyzing the evidence base for HaH programs that avoided 
inpatient admission (i.e., a “substitutive” model, 16 randomized trials with 1814 patients) verses 
those who focused on offering an avenue for early discharge (32 randomized trials with 4746 
patients) [12,31].  
Most early trials of HaH were conducted within single-payer health systems, limiting their 
applicability to the United States outside the VA. In 2005, a large multi-center quasi-experimental 
trial concluded that HaH was feasible, safe, and resulted in reduced length of stay and lower total 
costs [32]. The study focused on substitutive HaH for four medical illnesses (exacerbations of 
heart failure or COPD, pneumonia, and cellulitis) in elderly patients over 65. This was one of the 
first studies to show that patients in the HaH cohort had improvements in the functional status 
compared to traditionally-hospitalized patients, as measured by ability to complete instrumental 
activities of daily living and activities of daily living [33]. On cost analysis, they found significant 
cost savings for patients admitted for exacerbations of COPD and congestive heart failure but not 
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pneumonia nor cellulitis. For all diagnoses, the HaH cohort had significantly lower laboratory and 
procedure costs [14]. These results were validated by numerous models implemented across the 
country [15,27,34]. Since then, HaH programs have been created and studied at multiple large 
academic centers, including Johns Hopkins (Baltimore, MD), Mount Saini (New York City, NY), 
Presbyterian Health Services (New Mexico), and Brigham and Women’s Hospital (Boston, MA) 
[13,15,35,36]. The most recent randomized trial of 91 patients from the Brigham and Women’s 
Hospital showed cost savings of 38%, which included adjustment for demographics, patient 
education level, discharge diagnosis, and comorbidities. They found that patients hospitalized at 
home had fewer health interventions (labs, imaging, and consultations), were more active (less 
time sedentary or lying down), and had fewer re-admissions in 30 days [37].   
Despite the growing body of literature that shows clear benefits with HaH programs, it has not 
been widely disseminated in the United States, mainly due to lack of codified reimbursement, 
especially from Medicare, in a fee for service environment [27]. To address this gap, proposals 
were submitted to the national Department of Health and Human Services Physician-Focused 
Payment Model Technical Advisory Committee (PTAC) by Mount Saini (New York City, NY) 
and Marshfield Clinic (Marshfield, WI) outlining potential payment structures for HaH under 
Medicare fee-for-service [38,39]. The Mount Saini model was initially developed using a $9.6 
million grant from the Centers of Medicare and Medicaid Innovation to test bundle payment 
structures for HaH. While the Secretary of Health and Human Services chose not to implement 
either proposal at a national level, they indicated an interest in studying the concept further to 
create a sustainable payment mechanism [40]. In the absence of a national payment structure by 
Medicare fee-for-service, successful models have thrived in systems where incentives are aligned 
between payor and provider, such as Presbyterian Healthcare Services (New Mexico), whose 
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health plan covers 470,000 Medicare Advantage, Medicaid, and commercially insured patients 
[41]. The VA system offers Hospital-at-Home in 11 care sites and Cedars Sinai medical center in 
Los Angeles offers HaH for its managed care and accountable care organization patients [42]. A 
start-up called Medically Home (Boston, MA) hopes to implement HaH through a partnership with 
Atrius Health (MA), a non-profit health group with more than half million patients [43,44]. These 
developments show that HaH is poised for growth in the United States if the correct mix of 
reimbursement and health policy align to support its development. 
Globally, HaH has thrived in areas where payment structures support its growth. A prime example 
is the Australian state of Victoria, which includes the city of Melbourne. The state government’s 
decision to reimburse HaH at the same rate as a hospital inpatient admission has led to the growth 
of a vast hospital-in-the home system, matching the capacity of a 500-bed hospital with over 
32,000 admissions as year, representing 5% of all bed days in the state [11]. HaH is a complex 
multifaced intervention that requires appropriate patient selection, proper infrastructure, 
appropriate delivery of services, well-formed guidelines for patient monitoring and protocols in 
place to deal with deterioration in health. The success of the program in Victoria shows that HaH 
has the potential to be a potent tool to reduce the demand for beds in physical hospitals without 
compromising quality or patient satisfaction, while also providing cost savings to the system.  
Favorable Outcomes and Reduced Complications in HaH 
The last few decades have seen prolific scholarship on Hospital at Home, allowing for its efficacy 
to be tested across multiple health systems with a variety of different models. While there is much 
that remains unknown or unproven, there are multiple systematic reviews and meta-analyses 
examining feasibility and outcomes of the model. These reviews have found that outcomes for 
hospital at home are comparable to inpatient admission for a wide variety of diagnosis, there is 
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evidence of reduced patient harm, increased recovery, reduced mortality, and that treatment at 
home is both acceptable and even preferable for patients [12,45–48]. In properly selected patients, 
HaH has the potential to be applied to a wide variety of medical diagnosis and be comparable to 
an inpatient hospital admission, and may reduce some common complications seen in hospitalized 
patients. A meta-analysis of 61 randomized trials found a significant reduction in mortality, 
equivalent to one death prevented for every 50 patients admitted to HaH [47]. 
Hospital at Home has been validated in a wide variety of clinical diagnoses as being comparable 
to or even better than traditional hospitalization. For patients with acute exacerbation of heart 
failure, HaH showed no difference in cardiovascular mortality and led to improved quality of life, 
longer time to readmission and reduced costs [45]. HaH for COPD exacerbations showed 
significant reductions in readmission rates and a trend to toward reduced morality [46]. Treatment 
of deep vein thrombosis has been done in HaH programs, though data now suggests that outpatient 
treatment even without HaH is acceptable and reduces chances of recurrence compared to inpatient 
admission [11,49]. HaH has also been shown to be comparable to inpatient admission for selected 
cases of uncomplicated ischemic stroke, community acquired pneumonia, cellulitis, and for elderly 
patients with a broad range of medical diagnoses [12,48].  
In addition to having comparable clinical outcomes to inpatient hospitalization, HaH has also been 
shown to reduce risk of some complications seen with inpatient hospitalization. Hospital at home 
patients tend to be more physically active and spend more time out of bed [15,37]. They tend to 
have lower instances of hospital acquired disability and improved function measured by IADLs 
and ADLs [15,33]. Elderly patients in Hospital at home are significantly less likely to develop 
delirium [32,50,51]. Patients are less likely to require the use of sedative medications and chemical 
restraints when treated at home [32]. Further studies may show that Hospital at Home is an 
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effective way of reducing many other complications associated with inpatient admission without 
compromising quality. 
Oncology Hospital-at-Home 
As hospital at home has expanded in the United States and abroad, it has been proposed as a 
potential avenue of treatment for oncologic patients [10]. HaH could allow the provision of 
selected inpatient cancer care to be transitioned to the home setting. In addition to benefits 
mentioned above, HaH could be particularly beneficial in increasing the time cancer patients spend 
at home during a particularly vulnerable time. Increasing “home days” at the end of life has been 
identified as an important patient centered quality metric, and is particularly relevant for patients 
battling cancer diagnosis [52,53]. Models for HaH for oncology patients have been studied outside 
the United States, including at institutions in France, Australia, and Switzerland [54–56]. In the 
United States, the Huntsman Cancer Institute (Salt Lake City, UT) announced a 3-year hospital-
at-home trial starting in August 2018, and have enrolled 350 patients in the first year [57].  
Cancer patients are often admitted to the hospital for planned administration of chemotherapy or 
for unplanned complications of their diseases [58]. In unplanned hospitalizations they commonly 
present to the emergency room with pain, respiratory complaints, gastrointestinal complaints, 
malaise, neurologic complaints, and fever [8]. There is a growing body of evidence that even 
complex chemotherapy regimens and autologous stem cell transplantation can be safely performed 
at home for selected patients [54,56,59–61]. Fewer studies focus on HaH as a substitute for 
unplanned hospitalizations of cancer patients [62,63]. 
Administration of intensive chemotherapy has been successfully implemented in the home setting. 
A group in Switzerland delivered 11 systemic chemotherapy regimens at home in 17 patients, 
resulting an increase in patient comfort and a 53% reduction in cost [56]. Outpatient autologous 
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stem-cell transplantation has also been successfully piloted with 14/21 patients not requiring any 
inpatient admission despite complications such as neutropenic fever being common [60]. A 
systemic review of 24 studies examining home hospitalization for cancer drug administration 
found increased patient satisfaction, a patient preference for home treatment and no evidence of 
safety risks [61]. The Centre L´eon B´erard in France conducted a non-randomized study of 82 
patients and showed a cost savings of 34% for cancer patients receiving palliative care, while the 
savings for patients receiving chemotherapy was minor and not statistically significant [55]. The 
cost savings results of other studies across different countries show mixed results [61].  
In addition to the Centre L´eon B´erard using home hospitalization for patients receiving palliative 
care, studies have examined the use of outpatient treatment of two common complications seen in 
cancer patients. Febrile neutropenia has been successfully treated at home with clinical outcomes 
equivalent to inpatient hospitalization [63]. In addition, studies referenced above treated febrile 
neutropenia at home as a complication of home administration of chemotherapy. Cancer associated 
venous thromboembolism, including pulmonary embolism has also been treated in the home with 
comparable clinical outcomes [62].  
As outlined by Handley and Bekelman, challenges to widespread implementation of oncology 
HaH include inadequate tools for patient selections, lack of models for staffing, and resource 
allocation, and inadequate mechanisms of reimbursement [10]. The success of models created for 
general medical conditions in organizations like the VA and major academic medical centers in 
the United States shows that many of these challenges can be overcome. The ability to classify 
patients according to their risk of adverse events in HaH is critical to the development and success 
of a new HaH program. Due to the presence of certain specialized services, the Hospital will be a 
safer and more appropriate location of care for patients who are at risk of decompensation. On the 
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other hand, for patients who have a low risk of decompensation, the hospital may lead to unwanted 
complications or exposures. Developing tools to identify appropriate patients for oncology HaH is 
critical to its development and expansion. An examination of past cancer admissions allows for 
the preliminary development of such tools without putting patients at risk. These could be validated 
with prospective studies, similar to studies done to validate criteria for general hospital admissions 
[64]. Interest in innovative models of care delivery is growing within the field of oncology, and 
the changes in payment structures supports the development of such programs. The rise of the 
Oncology Care Model, an episode based payment structure created by Medicare that encourages 
cancer hospitals to take on risk, has caused cancer hospitals to think critically about the shift toward 
value based for cancer [65].  
This thesis uses historical data from patients at the Yale New Haven Hospital’s Smilow Cancer 
Hospital to create a predictive model that can be used to select appropriate patients for HaH 
consideration in a data-driven method. Yale New Haven Hospital (YNHH) has had a substantial 
growth of demand on its hospital beds and emergency rooms. This leads to longer wait times in 
the emergency department and extended boarding times in the emergency department as patients 
wait for an open bed. It has resulted in activations of the hospital’s emergency management plans 
to cope with a “surge crises.” This situation jeopardizes patient safety and quality of care [66]. 
This thesis aims to take preliminary steps toward developing a Hospital-at-Home program that 
could be part of the solution to reducing the demand for hospital beds. We focus on oncology 
admissions for two reasons: 1) The oncology care model is leading the way toward a value based 
payment structure that would incentivize programs like HaH, 2) Due to the potentially terminal 
nature of their diagnosis, giving patients with cancer more days at home could provide a valuable 
benefit to their quality of life [52]. 
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This study focuses specifically on oncology patients admitted for complications or 
decompensations, since little is known about the potential for HaH to be applied to that population. 
It represents the first step in developing evidence-based selection criteria for oncology HaH and 
will enable programs to maximize the likelihood that patients selected for HaH will be successfully 
cared for within this model while reducing the risk of adverse events. To our knowledge, this is 
the first study creating a predictive model to identify which medical oncology patients could be 
successfully treated in a HaH model.    
Statement of Purpose and Specific Aims 
The purpose of this study to derive and internally validate a predictive model to inform optimal 
selection of patients who may be cared for in an oncologic Hospital-at-Home.  
Aim 1: To identify the proportion of patients admitted to the oncologic floor that would have been 
suitable for hospital at home. 
Aim 2: Describe any demographic and outcomes differences between patients who were identified 
as suitable for hospital-at-home vs those who were not suitable. 
Aim 3: Develop and internally validate logistic prediction model based on a training cohort of 
index admissions to predict suitability using information available in the electronic medical record 
before the decision to admit the patient was made. 




We hypothesized that there exists a subset of patients admitted to the Yale medical oncology 
service who do not require specialized hospital services and would be suitable for treatment at 
home.  
We hypothesized that it would be possible to predict which subset of admissions would be least 
likely to require services only available in the hospital based on information available about the 
patient in the electronic health record prior to a physician’s decision to admit the patient to the 
hospital. We hypothesized the admission diagnosis, vitals, and lab results would have the strongest 
association with a patient’s potential eligibility for HaH. Based on previous HaH literature, we 
hypothesized that admission diagnosis of febrile neutropenia, infectious diseases, and cancer 
associated venous thromboembolism would predict higher eligibility for HaH compared to others. 
Respiratory distress, sepsis, and altered mental status have been shown to predict ICU admission 
and mortality in oncology admissions and we expected them to predict lower eligibility for hospital 
at home [7]. Tachycardia, tachypnea and low oxygen saturation have been shown to predict higher 
rates of rapid response team activation, and we predicted that they would also predict lower 
eligibility for hospital at home [67]. We expected anemia to predict lower suitability for HaH since 
concerns for Gastrointestinal hemorrhage could require specialist consultation and procedural 
intervention. We hypothesized that the type of cancer diagnosis and presence of metastatic disease 




Patient Selection  
Records for all patients admitted to the medical oncology floor (North Pavilion 12) of the Yale 
Smilow Cancer Hospital between 1/1/2015 and 6/12/2019 were obtained from the electronic 
medical record system (EPIC©, Verona, WI). All admissions that were transfers from outside 
hospitals or other health facilities (including skilled nursing, hospice and psychiatric facilities) 
were excluded because these patients were not living at home prior to the admission and would 
therefore be unsuitable for a HaH program. All patients whose primary reason for admission was 
chemotherapy were excluded from the study in order to focus on unplanned admissions. North 
Pavilion 12 at Yale New Haven Hospital is traditionally a solid tumor oncology floor, though 
recent bed shortages have resulted in hematologic malignancy patients being admitted there. For 
uniformity across time, all patients with a hematologic malignancy were excluded. Only patients 
initially admitted to the medical oncology floor were considered for this study in order to avoid 
transfers from higher levels of care or post-surgical patients.  
Defining Suitability for HaH 
Suitability for HaH was defined as the lack of decompensation, lack of surgical intervention or 
any specialty consultation that could potentially lead to procedural intervention, and not utilizing 
any hospital services that would be difficult or unsafe to provide in the home during an acute 
illness. This definition was based on services provided by recently published HaH programs and 
consultation with experts at Yale [27,34,37]. Decompensation was defined as escalation of care 
(to step-down or ICU) and/or the use of rapid response/code teams for urgent evaluation and 
intervention. All patients who received a surgery or interventional procedure were considered 
unsuitable. The following consult teams were categorized as potentially leading to procedural 
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intervention: all surgical services, interventional radiology, gastroenterology, pulmonology, 
interventional pain, radiation oncology, and dermatology. These services are often consulted in the 
inpatient setting in order to evaluate the patient for specific interventional procedures, which may 
be more difficult to provide in a HaH program. Other HaH programs in the United States have 
arranged for telemedicine specialist consults, which would be appropriate for non-interventional 
services [37]. While it may be possible to transport HaH patients temporarily to an imaging center 
for advanced imaging, this would require extra infrastructure and therefore all patients who had 
CT scans or MRIs were considered unsuitable. The following interventions were defined as being 
difficult or unsafe to perform in HaH model: physical or chemical restraints, nasogastric tubes, 
cardiac telemetry, and transfusion. Chemical restraints were defined as the intravenous or intra-
muscular prescription of any benzodiazepines or antipsychotics. Use of opioid analgesics was not 
a disqualifying factor since there exists precedence for the outpatient use of patient-controlled 
analgesia in patients with cancer [68,69] 
Differences between admissions identified as suitable and unsuitable were compared in order to 
accomplish aim 2 of this study. Suitable and unsuitable admissions were compared by 
demographics, length of stay, disposition, and readmissions in 30 days. Common admission and 
oncologic diagnoses were identified for suitable and unsuitable admissions. We identified that 
admissions to the oncology floor originated from the emergency department (ED), Oncology 
Extended Care Center (ECC), or directly from outpatient clinics. Directly admitted patients were 
admitted directly to the medical oncology floor after evaluation in a clinic, transfusion center, or 
other outpatient location. As per the Smilow cancer center guidelines, patients could not be directly 
admitted from home following a phone consultation with a provider, an in person evaluation was 
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required. We compared the proportion of suitable admissions from each source and the most 
common reasons for unsuitability.     
Data Preparation 
Predictors prepared for potential use in the model included demographics (age, sex, race, 
ethnicity), route of admission (from ED/ECC or directly from clinic), admission categorized as 
observation, primary admission diagnosis, pre-admission vitals, pre-admission labs, oncologic 
diagnosis, and admissions to the hospital or ED in the previous 90 days. The categorization of an 
admission as observation is based on criteria developed by hospitals and payors to identify which 
admissions do not require inpatient level services.   
Predictors that had lower than a 2% or higher than 98% prevalence in the derivation cohort were 
excluded in order to ensure an adequate number of observations for each characteristic. Predictors 
with greater than 20% missing data were excluded from analysis, as their clinical utility would be 
limited in future implementation efforts. We examined the missing data for associations with any 
known predictors in our data. Such an association would reject the assumption that our data is 
missing completely at random (MCAR), in favor of the assumption that it is missing at random 
(MAR) [70]. Under the assumption that our data would be missing at random, we planned to use 
multiple imputation to fill in missing values. As a secondary analysis we built a separate model 
with complete case analysis. Due to the large number of admissions and cancer diagnoses, the 
diagnosis ICD codes were grouped based on the multi-level clinical classification software 
(CCSR) developed by healthcare cost and utilization project (H-CUP) [71,72]. The classification 
groups ICD codes into CCSR groups based on similar pathology. For example, the ICD code for 
neutropenia (along with aplastic anemia and others) is grouped into the CCSR code for “diseases 
of white blood cells.” These CCSR codes are also grouped into larger disease categories. The 
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CCSR code for “diseases of white blood cells” is a group in the category of “disorders of blood.” 
Each CCSR code and category for admission and oncologic diagnosis were coded into binary 
indicator variables. Vitals and lab results were grouped into clinically relevant groupings, only 
categories with >2% prevalence in the sample were retained.   
Separation of Training and Validation Cohorts 
We included only the first admission for patients who had multiple admissions during the time 
period to avoid any interdependence of observations when using logistic regression. For the 
multiply imputed model, samples were divided into equal derivation and validation cohorts from 
all eligible patients. Characteristics of patients in the training and validation cohorts were 
compared using Pearson’s chi-squared test for categorical covariates and Wilcoxon rank-sum for 
continuous covariates in order to describe any significant differences between the two groups. 
Missing data were multiply imputed 20 times using chained equations [73]. For the complete case 
analysis patients with missing data for potential predictor covariates were removed from the study. 
The patient sample was randomly divided into equal sized validation and derivation cohorts and 
compared using the methods described above.  
Predictive Model Construction 
A multivariable logistic predictive model was built using a modified purposeful selection process 
described by Hosmer and Lemeshow [74,75]. Each model (complete case analysis and multiple 
imputation) followed similar model building steps outlined below.  
Univariate logistic regression was done for each of the prediction covariates and examined for 
significance. The initial model was constructed with covariates that were significant predictors 
with a p value of 0.25 or less. All covariates with a p-value of 0.25 or less were checked for 
correlation with each other. Variables with high correlation (>|0.7|) were added separately to the 
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model and the model likelihood ratio and change c-statistic was compared to choose the covariate 
with a significant likelihood ratio that had the greatest increase in the c-statistic. Upon running a 
logistic regression model with all covariates selected from the univariate regression, non-
significant covariates (p-value greater than 0.1) were removed in order of least significance. At 
each removal step, a likelihood ratio was used to compare the models to ensure the removed 
variable did not significantly contribute to the overall model. Confounding was evaluated as a 
change in the coefficients of any of the other significant covariates greater than 15% when 
compared to a model including the covariate in question. This process was repeated until the 
remaining model included all remaining covariates had a p-value less than 0.1 or were significant 
confounders. The Wald test was used to ensure that all covariates contributed significantly to the 
model. Any covariates not included in the original model with a p-value above 0.25 and were then 
added sequentially to the model. At each addition step, a likelihood ratio was used to compare 
whether the covariate added significantly to the model. Added variables were also checked for 
correlation with variables already in the model, and those that were highly correlated (>|0.7|) were 
excluded model in favor of the covariate already included. Once all variables in the second group 
were examined, the model was reduced iteratively using the same method used above, except only 
for covariates added in the second group. If they were found to be significant, admission and 
oncologic categories (groups of CCSR codes) were examined by code to see if major codes 
affected the model in the same direction (increased or decreased odds for suitability). If all major 
individual codes of a significant category affected the model in the same direction but were 
insignificant individually, the category was retained in the model. If a code was significant by 
itself, it was included independently, and the category was excluded to avoid problems with 
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collinearity. Categories with codes that spanned broad clinical syndromes (Signs and Symptoms) 
were not included in the model.  
Assessment of the Predictive Models 
The performance of the predictive models was assessed by measuring the area under the receiver 
operating curve for the model on both the training and validation cohorts. Hosmer-Lemeshow 
Goodness of fit testing was conducted using 10 groups [76]. The performance on training and 
validation cohorts was compared using chi-squared analysis of the area under the curve. The model 
created from the complete case analysis was compared with the model developed through multiple 
imputation using the c-statistic for derivation and validation cohorts. Significant covariates were 
compared between the models for direction of effect. In order to avoid bias caused by missing 
data, the model created through multiple imputation was used for further predictions [77–79]. The 
predicted suitability for HaH in the validation cohort was divided into quartiles and compared 
(using Hosmer-Lemeshow goodness of fit) to the observed suitability for HaH to assess the 
calibration of the model. 
Creation of Clinical Calculator 
A clinical calculator was created by multiplying all model coefficients by 10 and rounding to a 
whole number. The calculators scores were divided into quartiles based on predicted suitability 
used above for model calibration. 
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Suitability for HaH 
There were 6,852 patient admissions to the medical 
oncology floor of the Smilow Cancer hospital 
during the period of the interest. 3,322 admissions 
met the study inclusion criteria, of which 908 
(27.33%) were found to be suitable for HaH. The 
average length of stay for patients who were 
suitable for HaH was 2.79 vs 6.41 for patients who 
were unsuitable. 87.5% of patients identified as 
suitable for HaH were discharged home, a majority 
(56.2%) of them without services. In comparison, 
69.5% of admissions identified as unsuitable resulted in discharge to home, with most of the rest 
being discharged to skilled nursing facilities, hospice facilities, or expired during their stay (Table 
1). Only three patients identified as suitable expired during their hospital stay, compared to 125 
deaths in patients identified as unsuitable. Admissions deemed suitable were significantly less 
likely to be readmitted with 30 days (25.3% vs 31.5%). ED visits in the 30 days following the 
episode were similar between both groups.   
Table 1: Demographics, length of stay and disposition of admissions identified as unsuitable and suitable for HaH. This data 
includes all admissions included in study (including duplicate admissions of the same patient). P-values in bold are significant to 
the 0.05 level. 
 
Unsuitable for HaH Suitable for HaH P-value  
N=2,414 N=908 
 




   Female 1,145 (47.4%) 398 (43.8%) 
 














3,530 did not 
meet criteria
Figure 1: Flowchart of patient admissions to the Medical 
Oncology Floor Showing the number of Index admissions 






   White or Caucasian 1,985 (82.2%) 729 (80.3%) 
 
   Black or African 
American 
218 (9.0%) 100 (11.0%) 
 





   Hispanic or Latino 149 (6.2%) 77 (8.5%) 
 
   Non-Hispanic 2,249 (93.2%) 828 (91.2%) 
 
   Unknown 16 (0.7%) 3 (0.3%) 
 
Admission Source   <0.001 
   Direct Admit 899 (37.2%) 243 (26.8%)     
   From ED/ECC 1,515 (62.8%) 665 (73.2%)     




   Expired 125 (5.2%) 3 (0.3%) 
 
   Home or Self Care 795 (32.9%) 510 (56.2%) 
 
   Home-Health Care Svc 882 (36.5%) 284 (31.3%) 
 
   Hospice/Home 106 (4.4%) 26 (2.9%) 
 
   Hospice/Medical 
Facility 
171 (7.1%) 28 (3.1%) 
 
   Skilled Nursing Facility 291 (12.1%) 44 (4.8%) 
 
   Other 44 (1.8%) 13 (1.4%) 
 
ED visit 30-day post 
discharge 
613 (25.4%) 229 (25.2%) 0.92 
Readmission 30-day 
post discharge 
761 (31.5%) 230 (25.3%) <0.001 
 
The two most common primary admission diagnoses were abdominal pain and respiratory 
complaints (Table 2). The most common oncologic diagnoses were lung, pancreatic, colorectal, 
and breast cancers (Table 3). The proportion of admissions with certain diagnoses varied based on 
suitability for HaH, with statistically significant differences seen in abdominal pain, secondary 
malignancy, fever, and nervous system signs & symptoms. Abdominal pain and fever were more 
common in the suitable patients, while secondary malignancy and nervous system signs were less 
common in the suitable group. The proportion of admissions with colorectal cancer and secondary 
malignancies were statistically different between suitable and unsuitable admissions. The 
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proportion of colorectal cancer was higher among suitable patients while the proportion of 
secondary malignancy was lower.  
Table 2: Admission Diagnosis with greater than 2% cumulative prevalence separated by suitability for HaH. P-values in bold are 
significant to the 0.05 level. 
Primary Admission Diagnosis Unsuitable for HaH Suitable for HaH Total P-value  
N=2,414 N=908 N=3,322 
 
Abdominal pain and other 
digestive/abdominal pain 
151 (6.3%) 90 (9.9%) 241 
(7.3%) 
<0.001 
Respiratory signs and symptoms 141 (5.8%) 58 (6.4%) 199 
(6.0%) 
 0.55 
Secondary malignancies 161 (6.7%) 19 (2.1%) 180 
(5.4%) 
<0.001 
Fever 86 (3.6%) 65 (7.2%) 151 
(4.5%) 
<0.001 
Fluid and electrolyte disorders 110 (4.6%) 40 (4.4%) 150 
(4.5%) 
 0.85 
Nausea and vomiting 88 (3.6%) 36 (4.0%) 124 
(3.7%) 
 0.67 
Diseases of white blood cells 65 (2.7%) 34 (3.7%) 99 
(3.0%) 
 0.11 
Conditions due to neoplasm or the 
treatment of neoplasm 
67 (2.8%) 31 (3.4%) 98 
(3.0%) 
 0.33 
Other general signs and symptoms 69 (2.9%) 21 (2.3%) 90 
(2.7%) 
 0.39 
Nervous system signs and 
symptoms 
70 (2.9%) 7 (0.8%) 77 
(2.3%) 
<0.001 
Acute and unspecified renal failure 58 (2.4%) 17 (1.9%) 75 
(2.3%) 
 0.36 
Respiratory cancers 59 (2.4%) 16 (1.8%) 75 
(2.3%) 
 0.24 
Malaise and fatigue 49 (2.0%) 24 (2.6%) 73 
(2.2%) 
 0.28 
Bacterial infections 50 (2.1%) 22 (2.4%) 72 
(2.2%) 
 0.54 
Endocrine system cancers - 
pancreas 
59 (2.4%) 13 (1.4%) 72 
(2.2%) 
 0.074 




Table 3: Primary Oncologic for all admissions separated by suitability for HaH. P-values in bold are significant to the 0.05 level. 
Primary Oncologic Diagnosis Unsuitable for HaH Suitable for HaH Total p-value  
N=2,414 N=908 N=3,322 
 
Respiratory cancers 445 (18.4%) 168 (18.5%) 613 
(18.5%) 
 0.96 
Endocrine system cancers - 
pancreas 
240 (9.9%) 97 (10.7%) 337 
(10.1%) 
 0.53 





Breast cancer - all other types 221 (9.2%) 95 (10.5%) 316 
(9.5%) 
 0.25 
Urinary system cancers - kidney 118 (4.9%) 46 (5.1%) 164 
(4.9%) 
 0.83 
Skin cancers - melanoma 113 (4.7%) 41 (4.5%) 154 
(4.6%) 
 0.84 
Gastrointestinal cancers - stomach 84 (3.5%) 32 (3.5%) 116 
(3.5%) 
 0.95 
Urinary system cancers - bladder 85 (3.5%) 24 (2.6%) 109 
(3.3%) 
 0.21 
Male reproductive system cancers - 
prostrate 
78 (3.2%) 25 (2.8%) 103 
(3.1%) 
 0.48 
Gastrointestinal cancers - 
esophagus 
57 (2.4%) 24 (2.6%) 81 
(2.4%) 
 0.64 




The most common reasons for unsuitability for HaH were consult to a procedural service, use of 
chemical restrains, and use of advanced imaging. The frequency of these were statistically different 
based on route of admission (Table 4). More patients who were evaluated in the ED/ECC were 
suitable for HaH compared to admissions directly admitted from outpatient clinics. Admissions 
directly from clinic were significantly more likely to be unsuitable due to the use of interventional 
consults, chemical restraints, and advanced imaging.  
Table 4: Reasons for unsuitability for HaH in total and separated by route of admission. P-values in bold are significant to the 0.05 
level. 
Reason for Unsuitability Direct Admit ED/ECC Total P-value  
N=1,142 N=2,180 N=3,322 
 
Escalation of Care 42 (3.7%) 58 (2.7%) 100 (3.0%)  0.10 
Rapid Response 24 (2.1%) 42 (1.9%) 66 (2.0%)  0.73 
Code Blue 0 (0.0%) 0 (0.0%) 0 (0.0%) 
 
Surgery 148 (13.0%) 248 (11.4%) 396 
(11.9%) 
 0.18 
Consult to Procedural 
Service 
484 (42.4%) 807 (37.0%) 1,291 
(38.9%) 
 0.003 
Physical restraints 9 (0.8%) 22 (1.0%) 31 (0.9%)  0.53 
Chem restraints 350 (30.6%) 456 (20.9%) 806 
(24.3%) 
<0.001 
Nasogastric Tube 27 (2.4%) 31 (1.4%) 58 (1.7%)  0.049 
Telemetry 5 (0.4%) 7 (0.3%) 12 (0.4%)  0.59 





Advanced Imaging 603 (52.8%) 962 (44.1%) 1,565 
(47.1%) 
<0.001 




Creation of Derivation and Validation Cohorts 
Of the 3,322 admissions, 1,130 were repeat admissions during our time period of interest, the 
remaining 2,192 were used for model construction. Missing values were most common in lab and 
vitals, with direct admissions having a greater number of missing (Table 5). Measures with >20% 
missing values in the entire cohort were dropped from the multiple imputation model. Missing 
values for oncology diagnosis were not imputed since the oncology diagnosis was separated into 
a series of binary variables for each CCSR code. Multiple imputation using demographic and 
clinical predictors (in addition to suitability for HaH) was conducted 20 times for the reaming 
laboratory and vital sign values. 1,538 of the admissions had complete vitals and laboratory data 
prior to admission and were used to construct the complete case analysis model predictive model.  
Table 5: Missing values for the predictors missing >5% of values. Absolute neutrophil count, chloride and potassium were 
dropped from analysis due to >20% missing in the entire sample.  
 Admissions through ED/ECC Direct Admissions 
Value N Missing N Complete % Missing N Missing N Complete % Missing 
Absolute 
Neutrophil count 
352 1,087 24.46% 205 548 27.22% 
Potassium 246 1,193 17.10% 204 549 27.09% 
Bicarbonate 222 1,217 15.43% 203 550 26.96% 
Sodium 233 1,206 16.19% 202 551 26.83% 
Chloride 259 1,180 18.00% 202 551 26.83% 
BUN 234 1,205 16.26% 202 551 26.83% 
White Blood Cell 234 1,205 16.26% 198 555 26.29% 
Hemoglobin 233 1,206 16.19% 198 555 26.29% 
Platelets 235 1,204 16.33% 198 555 26.29% 
Final RR 65 1,374 4.52% 95 658 12.62% 
Initial RR 64 1,375 4.45% 94 659 12.48% 
Final Temperature 79 1,360 5.49% 91 662 12.08% 





49 1,390 3.41% 89 664 11.82% 
Initial Blood 
Pressure     
47 1,392 3.27% 88 665 11.69% 
Initial HR 48 1,391 3.34% 87 666 11.55% 
Final HR 49 1,390 3.41% 87 666 11.55% 
Oncology Diagnosis 84 1,355 5.84% 58 695 7.70% 
 
The entire cohort of 2,192 were divided randomly into derivation and validation cohorts. The 
characteristics of patients in the derivation and validation cohorts were similar in terms of 
demographics, reason for admission and oncologic diagnosis (Table 6). For the complete case 
analysis, the derivation and validation cohorts were constructed using the 1,538 complete cases, 
with random allocation done using the same random seed. Data for complete case analysis is 
presented in the appendix.   
Table 6: Training and Validation cohorts compared on a variety of patient and admission factors. Categorical variables were 
compared using Parsons’s chi2 and continuous variables using Wilcox Rank Sum.  Data presented as N (percentage) for 
categorical and mean (SD) for continuous measures. 








   Female 535 (48.8%) 519 (47.4%) 
 





   White or Caucasian 896 (81.8%) 896 (81.8%) 
 
   Black or African American 114 (10.4%) 103 (9.4%) 
 





   Hispanic or Latino 58 (5.3%) 68 (6.2%) 
 
   Non-Hispanic 1,028 (93.8%) 1,022 (93.2%) 
 
Primary Admission Diagnosis category 
  
 0.52 
   Blood Disorders 48 (4.4%) 66 (6.0%) 
 
   Circulatory Disorders  48 (4.4%) 38 (3.5%) 
 
   Digestive Disorders 97 (8.9%) 90 (8.2%) 
 
   Endocrine Disorders 76 (7.0%) 71 (6.5%) 
 




   Infections 31 (2.8%) 29 (2.7%) 
 
   Musculoskeletal Disorders 30 (2.7%) 26 (2.4%) 
 
   Neoplasm 252 (23.1%) 228 (20.9%) 
 
   Nervous System Disorders  20 (1.8%) 39 (3.6%) 
 
   Respiratory System Disorders 51 (4.7%) 49 (4.5%) 
 





   Breast 107 (10.6%) 112 (11.0%) 
 
   Endocrine 108 (10.7%) 120 (11.7%) 
 
   Gastrointestinal 221 (21.9%) 205 (20.1%) 
 
   Head & Neck 79 (7.8%) 61 (6.0%) 
 
   Male Reproductive 42 (4.2%) 44 (4.3%) 
 
   Respiratory/Cardiac 211 (20.9%) 231 (22.6%) 
 
   Secondary/Ill-defined Site 49 (4.8%) 42 (4.1%) 
 
   Skin 54 (5.3%) 56 (5.5%) 
 
   Urologic 83 (8.2%) 84 (8.2%) 
 
Comorbidities    
History of Myocardial Infarction 105 (9.6%) 94 (8.6%)  0.41 
Congestive Heart failure 148 (13.5%) 122 (11.1%)  
0.091 
Peripheral Vascular Disease 195 (17.8%) 192 (17.5%)  0.87 
History of Cerebral Vascular Accident 181 (16.5%) 191 (17.4%)  0.57 
Dementia 28 (2.6%) 18 (1.6%)  0.14 
Pulmonary Disease 407 (37.1%) 409 (37.3%)  0.93 
Rheumatic Disease 40 (3.6%) 47 (4.3%)  0.44 
Peptic Ulcer Disease 69 (6.3%) 74 (6.8%)  0.67 
Liver Disease 405 (37.0%) 435 (39.7%)  0.19 
Diabetes 274 (25.0%) 275 (25.1%)  0.96 
Metastatic Cancer 990 (90.3%) 985 (89.9%)  0.72 
Evaluated in ED/ECC 710 (64.8%) 729 (66.5%)  0.39 
Length of Stay 5.42 (5.37) 5.37 (5.01)  0.82 
Suitable for HaH 295 (26.9%) 295 (26.9%)  1.00 
 
Predictive Model Creation 
For the Multiple Imputation model, 19 predictors were included in the initial model based on their 
individual significance. The final model contained 13 predictors (Figure 2). Predictors of 
suitability for HaH (OR,p-value): observation status (10.15,0.000), admission for fever (3.21, 
0.000), final pre-admission temperature >100o F (1.79,0.015), admitted via ED/ECC (1.64,0.003), 
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sodium >135 mEq/L (1.64,0.007), African American Race (1.61, 0.051). Predictors of 
unsuitability for HaH (OR, p-value): oncology diagnosis of secondary or unknown malignancy 
(0.32, 0.024), initial pre-admission respiratory rate >20/min (0.38,0.032), admission for secondary 
malignancy (0.40,0.032), final pre-admission systolic blood pressure <100 (0.42,0.007), 
hemoglobin <10 (0.51,0.001), admission category of digestive disorders (0.57, 0.052), and 
previous ED visit in previous 90 days (0.68,0.015). 
All major codes in the CCSR category of “admission for digestive diseases” were not significant 
individually, but all were trending toward decreased suitability. The four most common (with 
N>10 each in derivation group) CCSR codes in the digestive disorders’ category were intestinal 
obstruction/ileus, noninfectious gastroenteritis, biliary tract disease and gastrointestinal 
hemorrhage. Codes for GI symptoms such as abdominal pain, nausea & vomiting, and diarrhea 
are not included in the digestive disorders’ category and were found to not be significant in the 
multiple imputation model. Oncology diagnosis category of secondary or unknown malignancy 
included only three CCSR codes, which were individually insignificant but all trending in the 
direction of decreased suitability. The three codes included unspecified malignant neoplasm, 
neoplasm of unspecified nature/uncertain origin, and secondary malignancy. There was no 
correlation between oncologic diagnosis of secondary malignancy and admission for secondary 
malignancy. On chart review, admission for secondary malignancy described patients who 
admitted for complications of metastatic solid tumors such as peritoneal carcinomatosis. African 
American race was significant compared to White/Caucasian race, other racial categories such as 
Asian or Native American did not meet the 2% prevalence cutoff and were grouped into “Other”. 
The “Other” category was not significant compared to “White/Caucasian” with an odds ratio of 
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0.98 (p value of 0.953). The choice of final vs initial value for each vital sign included in the model 
was based on which was more significant when added in separately (due to high correlation).    
The complete case analysis model (detailed in appendix) contained 13 significant predictors, of 
which 9 matched predictors in the multiply imputed model. The direction of effect and odds ratios 
for the covariates in common were similar. 
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Figure 2: Odds Ratios for significant predictors included after averaging analysis of 20 imputed data sets. The blue bars indicate 95% CI, with Odds Ratios listed in table below. 
The 95% CI for Observation status extends beyond the range of the graph. For predictors in which one category occurred at less than 2% prevalence ( RR<10, SBP >180,  Hgb>18  
& Sodium >145) the category was merged into the normal value. 
* The “Other” category within race contains race identified as “other” or “unknown” as well as Asian and Native American. The other category was not significant and is only 





Assessment of the Predictive Model 
Receiver Operating Curves (ROC) of the model showed moderate discrimination with c-statistics 
of 0.736 on derivation, and 0.686 on validation (Figure 3). The performance of the complete case 
analysis model was similar with c-statistics of 0.757 on derivation, and 0.683 on validation (Figure 
5 in appendix). There was a significant loss of model discrimination between the derivation and 
validation cohorts (p-value 0.044).  Hosmer-Lemeshow goodness of fit on the validation cohort 
showed good calibration with a p-value of 0.19 (10 groups). Quartiles of predicted suitability for 
HaH closely tracked actual proportion of suitable admissions for the validation cohort (Figure 4). 
The Hosmer-Lemeshow goodness of fit test for these four categories confirmed appropriate 




Figure 3: Receiver Operating Curve (ROC) of predictive model for suitability for HaH on derivation and validation cohorts. Chi2 
analysis used to compare area under the curve (c-statistic) between derivation and validation cohorts. 
 
 
Figure 4: Quartiles of predicted suitability for HaH compared to actual proportion of suitable admissions in the validation cohort. 
Bars on predicted values show full range of predicted probabilities within that quartile. 
 
Cohort N C-statistic std. 
error 
[95% Conf. Interval ] 
Derivation 1096 0.7359 0.0173 0.70203 0.7697 
Validation 1096 0.6857 0.018 0.65054 0.72091  
Ho: area(0) =  area(1) 
  
 
chi2(1) = 4.05 
 




Creation of Clinical Calculator 
A clinical calculator was created by multiply all model coefficients by 10 and rounding to a whole 
number. The quartiles were based on quartile ranges determined above during model calibration. 
Predictors Calculator Score 
Admitted as Observation +23 
Admission for Fever +12 
Black/African American Race +5 
Admitted via ED/ECC +5 
Sodium <135 mEq/L +5 
Final Temperature >100o F +3 
ED visit in last 90 days -4 
Admission for Digestive Diseases -6 
Hemoglobin <10 g/dl -7 
Final Systolic Blood Pressure <100 mmHg -9 
Admission for (complications of) Secondary Malignancy -9 
Oncology diagnosis of Secondary/Unknown Malignancy -11 
  
Quartile Cutoffs Predicted% Suitability 
≤ -4 14.5% 
-3 to 0 17.8% 
1 to 5 28.6% 







In a contemporary sample of patients hospitalized for oncologic disease at Yale New-Haven 
Hospital, we found that, 27% of admissions to the medical oncology floor were potentially suitable 
for HaH. The predictive model identified 13 significant predictors that combined to have a 
moderate discrimination (c-statistic of 0.69 on validation). The model was well calibrated to 
identify 4 quartiles of suitability for HaH, with the lowest quartile having a predicted suitability of 
12%, and the highest having a predicted suitability of 48%. A notable challenge to implementing 
a hospital at home program for oncology patients is identifying subsets of patients who are most 
likely to be suitable for care at home [10]. This predictive model has the potential to be used as a 
starting point to identifying subsets of oncology patients who could be treated in a substitutive 
hospital at home program. To our knowledge this is the first predictive model created for oncology 
patients to identify admissions suitable for HaH. While a few oncology HaH programs have been 
developed and studied around the world, there is limited literature on selection criteria for 
oncology patients admitted with acute illness related to their cancer or its treatment [54–56,61]. 
Admissions for acute illness and decompensation form a significant part of the total inpatient 
admissions in cancer patients, and can affect the patient’s quality of life, as well as total cost of 
care [4,6,8,58,72,80,81].  
Our work advances the development of oncologic hospital at home by beginning to address the 
challenge of patient selection [10]. For a HaH program to be successful it is important to select 
appropriate patients that would not require services difficult to deliver in the home. While HaH 
aims to deliver hospital level care in the home, it lacks the direct proximity to specialized care that 
is available in most hospitals. Intensive care units, rapid response teams, round the clock in-house 
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physician and nursing coverage, quick access to advanced imaging, and a full suite of consultants 
are unique to hospitals and cannot be replicated in a home. We attempted to create a model that 
would predict which patients do not require these hospital-specific services. Our results show that 
it is possible to group admissions by levels of suitability based on information available in the 
electronic medical record at the time of admission. Further studies can be done to prospectively 
validate the model and create a pilot HaH program for oncology patients. 
Our criteria for suitability were based on the conceptual framework of substitutive HaH [14,30,82]. 
Patients who at any point during their hospital admission required a service deemed difficult to 
provide at home were considered unsuitable, without considering the possibility of early discharge 
to HaH. Our criteria identified 908 admissions to the medical oncology floor during our time period 
of interest. This equates to a little over 200 admissions and 562 bed-days per year, enough to 
support a dedicated HaH team [83]. Patient admissions identified as suitable for HaH with our 
criteria had significantly lower length of hospital stays, were more likely to result in discharge to 
home, and less likely to be readmitted within 30 days. These statistically significant differences 
support the hypothesis that our definition of suitability identified patients who had a lower 
complexity of medical illness and better outcomes. The propensity of these patients to be safely 
discharged home after their hospital admission supports the possibility of them being cared for 
through a HaH program.   
Our predictive model showed moderate discrimination to predict suitability and was well 
calibrated across quartiles in our validation cohort. There were 13 significant predictors, 6 
predicted increased suitability, and 7 predicted unsuitability. Predictors of suitability for HaH: 
observation status, admission for fever, final temperature >100o F, admitted via ED/ECC, sodium 
>135 mmol/L, African American Race. Predictors of unsuitability for HaH: oncology diagnosis of 
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secondary or unknown malignancy, initial respiratory rate >20 /min, admission for secondary 
malignancy, final systolic blood pressure <100 mmHg, hemoglobin <10 g/dL, admission category 
of digestive disorders, and previous ED visit in previous 90 days. The predictor with the strongest 
odds ratio was observation status, which applied to only a small proportion of admissions (5.4%). 
Observation status is defined through criteria by Medicare and other payors and is used to classify 
admissions that do not require inpatient level care, which supports its relevance in our model.  
While age and sex were not significant predictors, we were surprised to find that race was a 
significant predicator. Since suitability for HaH is based on the complexity of medical care 
required during an admission, this result seems to indicate that with other significant predictors 
held constant, Black/African American cancer patients utilize less complex medical care during 
their admissions to the medical oncology floor. Racial disparities in healthcare in the United States 
are prevalent and can be observed through the higher un-insurance rates, lower access to care, and 
delaying of care due to cost amongst minority groups, especially African Americans [84]. Black 
cancer patients have higher mortality rates and shorter survival times [85]. In the context of our 
model, African American race may be correlated with decreased access to healthcare in an 
outpatient setting, resulting in more admissions for conditions that could have been cared for as an 
outpatient. 
At baseline, patients evaluated in the ED or ECC were more likely to be suitable for HaH compared 
to patients admitted directly from clinic. The reasons for this are likely to be multifactorial but can 
be partially explained by the increased use of advanced imaging and interventional consults after 
admission among patients admitted directly from clinic. These patients were admitted directly to 
the medical oncology floor after evaluation in a clinic, transfusion center, or other outpatient 
location. These locations may lack the easy access to consults and advanced imaging available in 
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the ED/ECC, delaying their use for these patients until they are admitted to the hospital. It is 
possible that patients admitted through the ED/ECC likely received relevant imaging and consults 
as part of their evaluation prior to admission. Since these actions occurred before admission, they 
were not considered when determining suitability for HaH, potentially contributing to the higher 
proportion of suitable admissions within the ED/ECC group. 
The primary admission diagnosis and cancer diagnosis of the patient contributed four significant 
predictors. Our model found that both admission for secondary malignancy and oncology 
diagnosis of secondary/unknown malignancy predicted lower suitability. The oncology diagnosis 
category for secondary/unknown malignancy was usually applied to patients whose tumors were 
diagnosed as metastatic or of unknown primary. The admission diagnosis of secondary malignancy 
applied to patients who were suffering from complications of metastatic disease (even with a 
known primary site). On further examination we found no correlation and almost no overlap 
between the two categories (only 0.3% admissions had both). Advanced stage cancer is common 
among cancer patients needing ICU admission and is associated with increased mortality [86]. In 
line with our hypothesis, admission for fever was predictive of increased suitability. While fever 
is a common reason for admission amongst cancer patients, it is not associated with increased risk 
for ICU admission or hospital mortality [7]. Admissions included under the category of “digestive 
disorders,” such as intestinal obstruction and biliary disease, are often evaluated by a variety of 
imaging modalities, especially CT scans. Increased use of advanced imaging in this group could 
be contributing to their decreased suitability.   
Vital signs and laboratory findings contributed five predictors to the model. Tachypnea with a 
respiratory rate >20 was predictive of lower suitability, similar to previous studies showing that 
cancer patients admitted with respiratory distress are more likely to require ICU care [7]. Final 
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pre-admission systolic blood pressure less than 100 was predictive of unsuitability. This is in line 
with a previous data showing that both increased respiratory rate and decreased systolic blood 
pressure measured in the ED before admission are strong predictors of ICU admissions and in-
hospital mortality [87]. Increased suitability associated with hyponatremia (sodium <135) could 
be due to admissions for complications such as fluid and electrolyte abnormalities or dehydration 
that do not pose high risk for decompensation. Since transfusion was a criterion for unsuitability, 
it was unsurprising that anemia was a strong predictor of unsuitability. 
ED admissions in the previous 90 days were predictive of unsuitability, likely a marker of the 
patient’s overall health status. Interestingly, hospital admissions in the last 90 days were significant 
on univariate analysis but was removed from the predictive models due to lack of significance 
once other factors were considered. This may be related to the intentional decision to use index 
admissions only, which may artificially limit the number of previous hospitalizations seen in our 
cohort. Any admission in which the patient was admitted to medical oncology in the past 90 days 
was excluded from analysis in favor of the earlier admission. 
There are some important limitations to our study that must considered. First, this study focuses 
on only one center, and may not reflect the patient population and treatment protocols at other 
cancer centers. Second, we only included admissions to the medical oncology floor, which limits 
the number and type of admissions. For a variety of reasons (such as bed availability, chief 
complaint, and severity of disease), cancer patients are often admitted to other parts of the hospital, 
including the general medicine ward. A more comprehensive study would examine the admissions 
of cancer patients to any hospital service. Third, in order to avoid confounding, we choose to 
include only the first admission for each patient within our time period. This decision excluded 
34% of the admissions during our time period of interest, thus reducing the power of our study. 
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Using the first admission for each patient may bias the sample toward admissions that occur are 
earlier on in the progression of a patient’s disease and are therefore less prone to complications 
that would limit suitability. Fourth, our definition of suitability was based only on clinical criteria. 
HaH programs also must include socioeconomic and convenience factors in defining suitability. 
Examples include distance of patient’s home to the hospital, layout of home, supportive home and 
family environment, patient frailty, mobility, and support of the patient’s family/caretakers. Fifth, 
the moderate discrimination of both models (c-statistic <0.7 on validation) means that a significant 
portion of the variability in suitability remains unexplained by our current model. If implemented 
in its current form, the model poses a significant risk of misalignment, where a substantial 
proportion of patients selected to be cared for through HaH may be unsuitable and could suffer 
adverse outcomes. While patients identified as unsuitable after admission to HaH could be 
transferred back to the hospital, it could still jeopardize or substantially delay appropriate patient 
care. This model could be improved through further studies in order to reduce the risk of 
misalignment. Further studies could consider the clinical judgement of the admitting physician, 
patient frailty, and functional status.  
Future models may also re-evaluate our definition of suitability, which was based on previous HaH 
programs in medical patients. It is possible that HaH programs developed for patients with 
oncology diagnosis may provide more services for this population. We discussed this possibility 
with leadership at the Smilow Cancer Hospital and identified three possible services that would be 
important for this patient group that are not included in many HaH programs: advanced imaging, 
telemedicine consultation with specialists, and in-home transfusion. Due to the frequent use of CT 
scans in population, a HaH program that could arrange for transport to the hospital for advanced 
imaging would be able to treat more patients. Telemedicine for expert consultation would allow 
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patients who need specialist care to also be part of a HaH program. For some patients, transfusions 
can be performed in the outpatient setting, and including that capacity in a HaH would be important 
to treat complications of chemotherapy. A HaH program with these capabilities would be able to 
provide more services than the one we envisioned when defining suitability, potentially increasing 
the pool of eligible patients.  
With these limitations, to the best of our knowledge, this study is the first to attempt to create 
guidelines for patient selection of oncologic hospital-at-home using a predictive model. The 
methods described here can be validated in other cancer centers to see if the significant predictors 
are similar across centers. Future work can focus on prospective validation of the model at Yale 
New Haven and refining the model to include clinician perception of suitability. Expansion of the 
model to all admissions of cancer patients, including general medicine floors could allow for a 
more comprehensive picture. The selection criteria can be further refined alongside development 







Complete Case Analysis Model: 
Table 7: Training and Validation cohorts compared on a variety of patient and admission factors. Categorical variables were 
compared using Parsons’s chi2 and continuous variables using Wilcox Rank Sum.  Data presented as N (percentage) for 
categorical and mean (SD) for continuous measures. 
Covariate Derivation Validation p-value 
 N=769 N=769  
Age  63.20 (12.22) 63.97 (12.62)  0.22 
SEX    0.88 
   Female 379 (49.3%) 382 (49.7%)  
   Male 390 (50.7%) 387 (50.3%)  
PRIMARYRACE    0.90 
   Black or African American 74 (9.6%) 81 (10.5%)  
   Other 27 (3.5%) 23 (3.0%)  
   Other/Not Listed 20 (2.6%) 15 (2.0%)  
   White or Caucasian 630 (81.9%) 626 (81.4%)  
ETHNICITY    0.11 
   Hispanic or Latino 58 (7.5%) 37 (4.8%)  
   Non-Hispanic 706 (91.8%) 728 (94.7%)  
   Patient Refused 1 (0.1%) 2 (0.3%)  
   Unknown 4 (0.5%) 2 (0.3%)  
Primary Admission Diagnosis Organ 
system 
   0.40 
   Blood 41 (5.3%) 34 (4.4%)  
   Circulatory  31 (4.0%) 27 (3.5%)  
   Digestive 77 (10.0%) 67 (8.7%)  
   Endocrine 58 (7.6%) 52 (6.8%)  
   Genitourinary 24 (3.1%) 38 (5.0%)  
   Infectious 21 (2.7%) 22 (2.9%)  
   Injury 11 (1.4%) 17 (2.2%)  
   Musculoskeletal 14 (1.8%) 22 (2.9%)  
   Neoplastic 155 (20.2%) 163 (21.3%)  
   Nervous system 19 (2.5%) 18 (2.3%)  
   Respiratory 27 (3.5%) 44 (5.7%)  
   Skin 16 (2.1%) 10 (1.3%)  
   Constitutional Signs & Symptoms 265 (34.5%) 245 (31.9%)  
Oncologic Diagnosis Category    0.64 
   Breast 81 (10.6%) 89 (11.7%)  
   Endocrine 86 (11.2%) 94 (12.4%)  
   Gastrointestinal 188 (24.6%) 151 (19.9%)  
   Gynecologic 8 (1.0%) 6 (0.8%)  
   Head & Neck 49 (6.4%) 42 (5.5%)  
   Male Reproductive 29 (3.8%) 28 (3.7%)  
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   Respiratory/Cardiac 164 (21.4%) 173 (22.8%) 
 
   Secondary/Ill-defined Site 35 (4.6%) 34 (4.5%) 
 
   Skin 27 (3.5%) 43 (5.7%) 
 
   Urologic 59 (7.7%) 65 (8.6%) 
 
Comorbidities:    
MI 80 (10.4%) 74 (9.6%)  0.61 
CHF 101 (13.1%) 90 (11.7%)  0.40 
Peripheral vascular disease 150 (19.5%) 136 (17.7%)  0.36 
Cerebrovascular accident 129 (16.8%) 129 (16.8%)  1.00 
Dementia 11 (1.4%) 19 (2.5%)  0.14 
Pulmonary disease 282 (36.7%) 281 (36.5%)  0.96 
Rheum 41 (5.3%) 26 (3.4%)  0.061 
Peptic Ulcer Disease 45 (5.9%) 50 (6.5%)  0.60 
Liver Disease 296 (38.5%) 306 (39.8%)  0.60 
Diabetes 202 (26.3%) 190 (24.7%)  0.48 
Metastatic Cancer 701 (91.2%) 705 (91.7%)  0.72 
Admission in prior 90 days 
  
 0.83 
   0 497 (64.6%) 507 (65.9%) 
 
   1 191 (24.8%) 181 (23.5%) 
 
   2 81 (10.5%) 81 (10.5%) 
 
ED admissions in prior 90 days 
  
 0.93 
   0 480 (62.4%) 482 (62.7%) 
 
   1 183 (23.8%) 186 (24.2%) 
 
   2 106 (13.8%) 101 (13.1%) 
 
Seen in ED/ECC 522 (67.9%) 530 (68.9%)  0.66 
Length of Stay 5.49 (5.35) 5.37 (5.02)  0.67 
Suitable for HaH 220 (28.6%) 221 (28.7%)  0.96 
 
Table 8: Final Predictive logistic model for complete case analysis containing 13 significant predictors. For predictors in which 
one category occurred at less than 2% prevalence (HR<50, RR<10, Hgb>18  & Sodium >145) the category was merged into the 
normal value.  
Predictor Odds 
Ratio 
P>z [95% Conf. Interval] 
Admitted as Observation 8.469375 0.000 4.016268 17.85995 
Admitted via ED/ECC 2.092021 0.000 1.405821 3.113163 
Admission for complications of 
Secondary Malignancy 
0.318486 0.021 0.12014 0.844293 
Admission for Fever 2.768015 0.004 1.387331 5.522765 
Admission for Nausea and Vomiting 2.529777 0.023 1.133531 5.645876 
Admission for Diseases of White Blood 
Cells 
2.440641 0.043 1.029571 5.785642 
Secondary or Unknown Malignancy 0.249061 0.028 0.071993 0.861628 
History of MI 1.840362 0.024 1.084262 3.123721 
Initial HR >100 1.383503 0.080 0.961411 1.990908 
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Initial RR>20 0.32007 0.049 0.102803 0.996519 
Sodium <135 1.77694 0.002 1.233508 2.559787 
Hgb < 10 0.318116 0.000 0.202105 0.50072 
ED admission in last 90 days 0.584995 0.005 0.403481 0.848167 
 
The area under the curve (AUC) in the receiver operating curve for the model was 0.7313 for derivation 
cohort and 0.6769 for the validation cohort (figure 2). Pearson’s Chi2 comparison between the two AUC 
curves showed that the model performed better for the derivation as compared to the validation cohort 
(Table 1). Visual comparison of kernel density plots for suitable and unsuitable patients shows similar 
density distributions in both derivation and validation cohorts (figure 3). 
Figure 5: Comparison of receiver operating curves for the model on derivation and validation cohorts for complete case analysis 
model 
 
Table 9: Comparison of the area under the curve for model on derivation and validation cohorts. Area compared using Pearson 
Chi2 test. 
Group Obs Area Std. Err. [95% Conf. Interval]       
Derivation (0) 769 0.7567 0.0190 0.71943 0.79402 
Validation (1) 769 0.6833 0.0218 0.64052 0.72610       
Ho: area(0) = area(1) 
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